lu 135252 has been researched along with nitrates in 1 studies
| Studies (lu 135252) | Trials (lu 135252) | Recent Studies (post-2010) (lu 135252) | Studies (nitrates) | Trials (nitrates) | Recent Studies (post-2010) (nitrates) |
|---|---|---|---|---|---|
| 196 | 13 | 14 | 31,630 | 1,022 | 11,067 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| deGottardi, A; Enseleit, F; Hürlimann, D; Lüscher, TF; Noll, G; Quaschning, T; Rossier, MF; Ruschitzka, F; Shaw, SG | 1 |
1 other study(ies) available for lu 135252 and nitrates
| Article | Year |
|---|---|
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Acetylcholine; Animals; Blood Pressure; Body Weight; Cells, Cultured; Corticosterone; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Gene Expression Regulation; Glycyrrhizic Acid; Heart Rate; Humans; Hydroxysteroid Dehydrogenases; Hypertension; Male; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Norepinephrine; Phenylpropionates; Potassium Chloride; Protein Precursors; Pyrimidines; Rats; Rats, Inbred WKY; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; RNA, Messenger; Vascular Diseases; Vasoconstriction; Vasodilation; Vasodilator Agents; Verapamil | 2001 |